Skip to main content
SpringerLink
Log in

E 4031

  • Section 1: Antiarrhythmic Agent
  • ADIS R&D PROFILE
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Mihara M, Tomono Y, Hasegawa J, et al. Pharmacokinetics and bioavailability of a new class III antiarrhythmic drug (E4031) in healthy volunteers. Cardiovasc Drugs Ther 1991; 5 Suppl. 3: 394

    Google Scholar 

  2. Mihara M, Asano Y, Hasegawa J. Pharmacokinetics of a new class III antiarrhythmic agent, E 4031, in normal adult subjects. Rinsho Yakuri 1992; 23: 303–4

    Article  Google Scholar 

  3. Buchanan LV, Kabell G, Brunden MN, et al. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK- 68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 1993; 220: 540–9

    Google Scholar 

  4. Imamura H, Furukawa Y, Yamazaki K, et al. Atrioventricular junctional rhythm induced by sympathetic stimulation in E-4031- treated dog hearts. J Cardiovasc Pharmacol 1996; 28: 507–12

    Article  PubMed  CAS  Google Scholar 

  5. Isomoto S, Shimizu A, Konoe A, et al. Electrophysiologic effects of E-4031, a new class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. Am J Cardiol 1993; 71: 1464–7

    Article  PubMed  CAS  Google Scholar 

  6. Carmeliet E. Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc Drugs Ther 1993; 7 Suppl. 3: 599–604

    Article  PubMed  Google Scholar 

  7. Lee KS, Tsai TD, Lee EW. Membrane activity of class III antiarrhythmic compounds: a comparison between ibutilide, dsotolol, E-4031, sematilide and dofetilide. Eur J Pharmacol 1993; 234: 43–53

    Article  PubMed  CAS  Google Scholar 

  8. Ohler A, Amos GJ, Wettwer E, et al. Frequency-dependent effects of E-4031, almokalant, dofetilide and tedisamil on action potential duration: no evidence for reverse use dependent block. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 602–10

    Article  PubMed  CAS  Google Scholar 

  9. Ohler A, Ravens U. Effects of E-4031, almokalant and tedisamil on postrest action potential duration of human papillary muscles. J Pharmacol Exp Ther 1994; 270: 460–5

    PubMed  CAS  Google Scholar 

  10. Mori K, Hara Y, Saito T, et al. Anticholinergic effects of class III antiarrhythmic drugs in guinea pig atrial cells: different molecular mechanisms. Circulation 1995; 91: 2834–43

    Article  PubMed  CAS  Google Scholar 

  11. Tohse N, Kanno M. Effects of dofetilide on membrane currents in sinoatrial node cells of rabbit. Jpn J Pharmacol 1995; 69: 303–9

    Article  PubMed  CAS  Google Scholar 

  12. Cheng J, Kamiya K, Kodama I, et al. Comparative study of new class III antiarrhythmic drugs, E-5031 and MS-551, on electrophysiological properties in single rabbit ventricular myocytes. Jpn J Pharmacol 1993; 61 Suppl. I: 99P

    Google Scholar 

  13. Abrahamsson C, Duker G, Lundberg C, et al. Electrophysiological and inotropic effects of H 234/09 (almokalant) in vitro: a comparison with two other novel IK blocking drugs, UK-68,798 (dofetilide) and E-4031. Cardiovasc Res 1993; 27: 861–7

    Article  PubMed  CAS  Google Scholar 

  14. Saville VL, MacKenzie I, Carr MG, et al. Glibenclamide, but not the class III compound E-4031, prolongs ischaemic action potentials in guinea-pig papillary muscle. Br J Pharmacol 1991; 104 Suppl.: 21P

    Google Scholar 

  15. Baskin EP, Lynch Jr JJ. Comparative effects of increased extracellular potassium and pacing frequency on the class III activities of methanesulfonanilide IKr blockers dofetilide, D-sotalol, E-4031, and MK-499. J Cardiovasc Pharmacol 1994; 24: 199–208

    PubMed  CAS  Google Scholar 

  16. Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol 1996; 27: 159–66

    Article  PubMed  CAS  Google Scholar 

  17. Wettwer E, Scholtysik G, Schaad A, et al. Effects of the new class III antiarrhythmic drug E-4031 on myocardial contractility and electrophysiological parameters. J Cardiovasc Pharmacol 1991; 17: 480–7

    Article  PubMed  CAS  Google Scholar 

  18. Adaniya H, Hiraoka M. Effects of a novel class III antiarrhythmic agent, E-4031, on reentrant tachycardias in rabbit right atrium. J Cardiovasc Pharmacol 1990; 15: 976–82

    Article  PubMed  CAS  Google Scholar 

  19. Inoue M, Inoue D, Ishibashi K, et al. Effects of E-4031 on atrial fibrillation threshold in guinea pig atria: comparative study with class I antiarrhythmic drugs. J Cardiovasc Pharmacol 1994; 24: 534–41

    Article  PubMed  CAS  Google Scholar 

  20. Wallace AA, Stupienski III RF, Brookes LM, et al. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol 1991; 18: 687–95

    Article  PubMed  CAS  Google Scholar 

  21. Spinelli W, Parsons RW, Colatsky TJ. Effects of WAY-123,398, a new class III antiarrhythmic agent, on cardiac refractoriness and ventricular fibrillation threshold in anesthetized dogs: a comparison with UK-68798, E-4031, and dl-sotalol. J Cardiovasc Pharmacol 1992; 20: 913–22

    Article  PubMed  CAS  Google Scholar 

  22. Shimizu A, Kaibara M, Centurion OA, et al. Electrophysiologic effects of a new class III antiarrhythmic agent, E-4031, on atrial flutter, atrial refractoriness, and conduction delay in a canine sterile pericarditis model. J Cardiovasc Pharmacol 1993; 21: 656–62

    Article  PubMed  CAS  Google Scholar 

  23. Ogawa S, Mitamura H, Katoh H. Effect of E-4031, a new class III antiarrhythmic drug, on reentrant ventricular arrhythmias: comparison with conventional class I drugs. Cardiovasc Drugs Ther 1993; 7 Suppl. 3: 621–6

    Article  PubMed  Google Scholar 

  24. Usui M, Inoue H, Saihara S, et al. Antifibrillatory effects of class III antiarrhythmic drugs: comparative study with flecainide. J Cardiovasc Pharmacol 1993; 21: 376–83

    Article  PubMed  CAS  Google Scholar 

  25. Chi L, Mu D-X, Lucchesi BR. Electrophysiology and antiarrhythmic actions of E-4031 in the experimental animal model of sudden coronary death. J Cardiovasc Pharmacol 1991; 17: 285–95

    Article  PubMed  CAS  Google Scholar 

  26. Takatsuki S, Mitamura H, Sueyoshi K, et al. Discordant prolongation of the refractory period and repolarization time by a class III agent, E4031, in the healing phase of myocardial infarction. Jpn Heart J 1998; 39: 687–97

    Article  PubMed  CAS  Google Scholar 

  27. Yamazaki K, Furukawa Y, Kasama M, et al. Negative chronotropic and dromotropic effects of E-4031, an I(Kr) blocker, on the atrioventricular node in anesthetized dog hearts. Eur J Pharmacol 1996; 297: 233–9

    Article  PubMed  CAS  Google Scholar 

  28. Sadanaga T, Ogawa S, Okada Y, et al. Clinical evaluation of the use-dependent QRS prolongation and the reverse usedependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J 1993; 126: 114–21

    Article  PubMed  CAS  Google Scholar 

  29. Fujiki A, Tani M, Mizumaki K, et al. Electrophysiologic effects of intravenous E-4031, a novel class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 1994; 23: 374–8

    PubMed  CAS  Google Scholar 

  30. Shimizu A, Fukatani M, Konoe A, et al. Electrophysiological effects of a new class III antiarrhythmic agent (E-4031) on the conduction and refractoriness of the in vivo human atrium. Cardiovasc Res 1993; 27: 1333–8

    Article  PubMed  CAS  Google Scholar 

  31. Okada Y, Ogawa S, Sadanaga T, et al. Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-hour holter electrocardiography. J Am Coll Cardiol 1996; 27: 84–9

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

E 4031. Drugs in R&D 1, 312–316 (1999). https://doi.org/10.2165/00126839-199901040-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199901040-00006

Keywords

Search

Navigation